C-L5PAstem cell-derived secretomes, extracellular vesicles, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Micregen states that ageing and poor health are creating a growing global burden, and that this can be improved by enhancing general health, increasing recovery speed from illness, and expanding treatment capacity. The company says it was founded to translate stem cell scientists' lifelong work into bedside therapies, developing stem cell-derived therapeutics intended to improve treatment outcomes, accelerate patient recovery, increase patient throughput, and reduce deaths and costs, while overcoming barriers that have limited clinical translation of stem cell technology.
SourceMicregen states that ageing and poor population health are creating a growing global burden on health services, and that this can be improved by better general health, faster recovery from illness, and sufficient treatment capacity. The company presents itself as a biotech research firm developing proprietary, regulatory-approved stem cell therapeutics intended to improve treatment outcomes, accelerate recovery, increase patient throughput, and reduce deaths and costs, based on the belief that stem cells can drive regeneration, rejuvenation, and disease amelioration across many clinical areas.
SourceMicregen states that ageing and poor population health are creating growing pressure on health services, and that this can be improved by better general health, faster recovery from illness, and enough treatment capacity. The company presents stem cell therapeutics as a way to significantly improve treatment outcomes, accelerate patient recovery, increase patient throughput, save lives and reduce costs, while translating regenerative and rejuvenation-focused stem cell science into clinical medicine.
SourceMicregen states that stem cells can be deliberately manipulated to produce potent secretions called Secretomix, and that these secretions can drive repair by reducing inflammation and scarring, improving blood flow, and creating a pro-regenerative microenvironment across many organs and tissues. The company believes this approach could change how critical and chronic conditions are managed, while avoiding the risks and limitations of whole-cell transplant and other current stem cell treatments.
SourceMicregen presents the view that population ageing and poor health are creating a growing global burden, and that this can be improved through stem cell therapeutics that enhance treatment outcomes, accelerate recovery, and expand care capacity. The company frames its work around translating stem cell science into clinical medicine by understanding how stem cells drive regeneration, rejuvenation, and disease amelioration.
Source